A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Nexstim Oyj: Nexstim Receives an NBS System Order from Australia
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or ) announces having received a purchase order for an NBS 5 system from Australia.
Earlier this week the company told it had been authorized by the Australian Therapeutic Goods Administration (TGA) to distribute the NBS system in Australia. Nexstim has also previously been granted authorization to sell and market its NBT system in the Australian market.
The clinical neuroscience company, based in Melbourne, is pleased to integrate NBS and NBT systems within their practice in addition to a rigorous research program to introduce Nexstim technology in neurosurgery.
Registration of the reduced quantity of shares in Nexstim Plc (the first phase) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nexstim Oyj: Impressive New Study Results Suggest Potential New Therapeutic Use for Nexstim SmartFocus nTMS in Postsurgical Rehabilitation of Paresis
SmartFocus in Postsurgical Rehabilitation of Paresis
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a new study published in
Brain Stimulation in May reports that the therapeutic use of Nexstim navigated repetitive transcranial magnetic stimulation (nrTMS) significantly improved outcomes for glioma patients suffering from post-surgical paresis. The study suggests that patients who suffer from a severe decline in hand function after brain tumor surgery can be treated post-operatively for 7 days with 15 minutes of nrTMS plus 30 minutes of physiotherapy per day.
Nexstim Oyj: Registration of the reduced quantity of shares in Nexstim Plc (the first phase)
Registration of the reduced quantity of shares in Nexstim Plc (the first phase)
The Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ), resolved on 11 May 2021 to reduce the quantity of Nexstim s shares without reducing share capital by way of issuing new shares and by redemption of Company s own shares, in such a way that each current 100 shares of the Company shall correspond to one share of the Company after the arrangements related to the reduction of the quantity of Company s shares are completed.